Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
Saci-IO TNBC
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- NCT04468061 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on Saci-IO TNBC (sacituzumab govitecan and pembrolizumab in Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Saci-IO TNBC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative
- Interventions
- Sacituzumab Govitecan; Pembrolizumab
- Arms
- Sacituzumab Govitecan + Pembrolizumab · Experimental
- Sacituzumab Govitecan · Experimental
- Retreatment · Experimental
- Enrollment
- 110 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Dana-Farber Cancer Institute with Gilead Sciences, Merck Sharp & Dohme LLC
- Start
- Jul 20, 2020
- Primary completion
- Apr 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04468061 · updated Apr 29, 2026
Publications
linked from the registry- Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):279-285. doi: 10.1097/COC.0000000000000919. Epub 2022 May 12. PubMed 35728046